首页> 外文期刊>World Journal of Gastroenterology >NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines
【24h】

NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines

机译:硫嘌呤治疗炎症性肠病患者血液学图片上的NUDT15变体

获取原文
           

摘要

AIM The single nucleotide polymorphism (SNP) c.415C>T in exon 3 of NUDT15 affects thiopurine-induced leukopenia in Asian patients with Crohn’s disease. Meanwhile, three additional genetic variants of NUDT15 were reported in patients with acute lymphoblastic leukemia. We evaluated the effects of these additional genetic variants of NUDT15 in patients with inflammatory bowel disease (IBD) treated with thiopurines. METHODS Ninety-six Japanese patients with IBD were enrolled. Genotyping for the NUDT15 and TPMT genes was performed using Custom TaqMan SNP genotyping assays or Sanger sequencing. The changes in white blood cell (WBC) count, mean corpuscular volume (MCV), platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT, and ESR were evaluated. RESULTS Genetic variants of exon 1 and exon 3 of NUDT15 were identified in 24 of 96 patients (25.0%). C.52G > A and c.36_37insGGAGTC in exon 1 were found in three patients each. All three patients with c.36_37insGGAGTC in exon 1 were heterozygotes of p.Arg139Cys in exon 3. Eighteen patients had p.Arg139Cys in exon 3 alone. The WBC count gradually decreased after initiation of thiopurine treatment in the mutated cases ( n = 24), and was significantly lower at 6, 8, 10, and 16 wk ( P = 0.0271, 0.0037, 0.0051, and 0.0185, respectively). The WBC counts were also evaluated in patients with and without prednisolone treatment. In the patients with prednisolone treatment, the WBC count tended to show a greater decrease in the mutated cases, with significant differences at 8 and 10 wk ( P = 0.012 and 0.029, respectively). In the patients without prednisolone treatment, the WBC count was significantly lower at 2, 4, 8, and 14 wk in mutated cases ( P = 0.0196, 0.0182, 0.0237 and 0.0241, respectively). MCV increased after starting thiopurine treatment in the mutated cases, and was significantly higher at 10 wk ( P = 0.0085). Platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT and ESR did not differ significantly between the wild-type and mutated cases. TPMT mutations were not found in any of the patients. CONCLUSION Mutations in exon 1 of NUDT15 also affect thiopurine-induced leukopenia in patients with IBD. To discuss thiopurine-induced leukopenia in more detail, investigation of SNPs in both exon 1 and exon 3 of NUDT15 is needed.
机译:目的:NUDT15外显子3中的单核苷酸多态性(SNP)c.415C> T影响硫代嘌呤诱导的亚洲克罗恩病患者的白细胞减少症。同时,在急性淋巴细胞性白血病患者中还报告了NUDT15的三个其他遗传变异。我们评估了NUDT15的这些其他遗传变异在用硫嘌呤治疗的炎症性肠病(IBD)患者中的作用。方法纳入96例日本IBD患者。 NUDT15和TPMT基因的基因分型使用Custom TaqMan SNP基因分型分析或Sanger测序进行。评估白细胞(WBC)计数,平均红细胞体积(MCV),血小板计数,血红蛋白,CRP,淀粉酶,白蛋白,AST,ALT和ESR的变化。结果在96例患者中有24例(25.0%)发现了NUDT15外显子1和外显子3的遗传变异。在三名患者中分别发现外显子1中的C.52G> A和c.36_37insGGAGTC。外显子1的c.36_37insGGAGTC的所有三名患者都是外显子3中p.Arg139Cys的杂合子。仅在外显子3中有18名患者有p.Arg139Cys。在突变病例中,开始进行硫嘌呤治疗后,WBC计数逐渐降低(n = 24),在6、8、10和16 wk时明显降低(分别为P = 0.0271、0.0037、0.0051和0.0185)。还在接受或未接受泼尼松龙治疗的患者中评估了白细胞计数。在泼尼松龙治疗的患者中,突变患者的白细胞计数趋于更大,在8周和10周时差异显着(分别为P = 0.012和0.029)。在未接受泼尼松龙治疗的患者中,突变患者的白细胞计数在2、4、8、14 wk时显着降低(分别为P = 0.0196、0.0182、0.0237和0.0241)。在突变病例中,开始使用硫嘌呤治疗后,MCV升高,在10周时显着升高(P = 0.0085)。野生型和突变型病例之间的血小板计数,血红蛋白,CRP,淀粉酶,白蛋白,AST,ALT和ESR均无显着差异。在所有患者中均未发现TPMT突变。结论NUDT15外显子1的突变也会影响硫代嘌呤诱导的IBD患者白细胞减少。为了更详细地讨论硫嘌呤诱导的白细胞减少症,需要研究NUDT15外显子1和外显子3中的SNP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号